Autism Spectrum Disorders Market Report and Forecast 2025-2034
Description
The autism spectrum disorders market was valued at USD 4.68 Billion in 2024 driven by increasing incidence of the condition and rising research activities to combat comorbidities associated with the condition across the 8 major markets. It is expected to grow at a CAGR of 5.20% during the forecast period of 2025-2034 and attain a market value of USD 7.77 Billion by 2034.
Autism Spectrum Disorders Market Overview
Autism spectrum disorder (ASD) is a neurological disorder affecting a person's ability to interact, communicate, behave, and learn. It is termed as a ‘developmental disorder’ as the symptoms appear within the first two years of life. Diagnosis is generally based on a child’s behavior. Most children are diagnosed at the age of 4. Approximately 1 in 36 (around 2.8%) children have been identified with the condition, with boys being more susceptible to developing the disease than girls. The male-to-female disease prevalence is 4:1. Around 40% of the children diagnosed with autism are nonverbal, while 44% of them have the average or above-average intellectual ability and 31% may have an intellectual disability. It may also affect a child’s ability to move and pay attention.
The autism spectrum market demand is driven by the growing number of ASD cases which augments the need for effective therapies, diagnostic tools, and support services. ASD research and treatment programs are increasingly receiving financial backing from the government, which also affects market dynamics. The growth of digital therapeutics and apps further boosts the market share by providing interactive and personalized therapy options. Moreover, the rising development of new therapies to manage symptoms and comorbid conditions associated with ASD is likely to support market expansion.
Autism Spectrum Disorders Market Growth Drivers
Increasing Prevalence of Autism Spectrum Disorder Set to Fuel Market Growth
The prevalence rates vary across different regions, with some areas having higher prevalence rates. For instance, California has an incidence of 1 in 26 patients, while South Korea has 1 in 38 patients affected by autism. The market is driven by the increasing prevalence of the disease, as the cases reported in 2023 saw a surge of 317% compared to 2000. The prevalence rates in adults are comparatively lower than children. In the United States, approximately 2.2% of the adults are autistic. The increased focus on programs and services aimed at helping individuals with ASD transition to adulthood is anticipated to shape the market dynamics.
Emphasis on Treating Autism Associated Comorbidities to Affect the Autism Spectrum Disorders Market Value Significantly
Recent data reveals that 38% of the patients with ASD experience seizures while 40% suffer from anxiety. Sleep issues affect 53% of the people. The market value of autism spectrum disorders is boosted by the application of new technologies to address rare comorbidities associated with the disease. In February 2023, a group of Northwestern researchers devised a new therapy to treat Phelan-McDermid syndrome, which is a rare subtype of ASD. The new drug is designed to address cognitive function, and motor behavior deficiencies among others. Moreover, there is a key focus on expanding the existing treatment options for adults as well, which is poised to boost market size.
Autism Spectrum Disorders Market Trends
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
Rising Utilization of Mobile Applications to Manage Autism
One of the major market trends is the growing utilization of digital health solutions such as mobile apps for ASD management. For example, in May 2023, BlueSprig Pediatrics, a United States-based prominent autism therapy provider launched the Attend Behavior App to provide individualized and effective behavioral strategies for children suffering from autism, ADHD, and other behavioral conditions. With the app, parents can receive real-time support and guidance to help their children. The rising integration and utilization of mobile apps are expected to benefit the market growth in the forecast period.
Increased Collaborations to Develop Efficient Treatment
The autism spectrum disorders market share is influenced by the increased collaborations among the key market players. For instance, in June 2023, PaxMedica, Inc. entered a strategic partnership with PoloMar Health to investigate the use of emodin as a potential treatment for treating autism spectrum disorder. PoloMar Health is also working with the BRAIN Foundation as a part of this initiative. The rising collaborations amongst companies to deliver effective and efficient solutions are anticipated to bolster the market share.
Growing Focus on Alternative Therapies
One treatment cannot help all the patients, therefore, there has been increasing importance on developing new therapeutics that address a wider spectrum of symptoms in the autism spectrum disorders market. Behavior therapy, speech-language therapy, physical therapy, and occupational therapy are common treatment methods in the market. Applied behavior analysis is a prominent behavioral treatment with two discrete trial training and pivotal response training as major categories. In addition, the researchers are continuously working to identify new potential treatments.
Advancements in Diagnosis and Treatment
The market is witnessing increased use of artificial intelligence (AI) and machine learning (ML) to facilitate early diagnosis and personalized treatment plans, with AI-driven tools showing the potential to improve the accuracy of autism spectrum disorder diagnosis. Moreover, advancements in wearable technology, such as smartwatches and biosensors, to monitor behavioral and physiological indicators in real time are expected to support the market expansion.
Autism Spectrum Disorders Market Segmentation
Autism Spectrum Disorders Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type Applied Behavior Analysis (ABA)
Speech and Language Therapy
Occupational Therapy
Others Antipsychotic Drugs
Selective Serotonin Reuptake Inhibitors (SSRIs)
Stimulants
Sleep Medications
Others
Market Breakup by Age Group Germany
France
Italy
Spain
United Kingdom
Market Segmentation Based on Application Areas is Anticipated to Witness Substantial Growth
Based on the treatment type, the market is segmented into communication and behavioral therapies and drug therapies. Communication and behavioral therapies include applied behavior analysis (ABA), speech and language therapy, and occupational therapy, among others, whereas drug therapies are further segmented into antipsychotic drugs, selective serotonin reuptake inhibitors (SSRIs), stimulants, and sleep medications, among others.
The communication and behavioral therapies segment holds a significant share of the autism spectrum disorders market. This can be attributed to the established effectiveness of behavioral therapies in improving the quality of life for people living with autism spectrum disorder. Behavioral therapies, such as applied behavior analysis (ABA), are widely used to improve social skills, communication, and adaptive behaviors in ASD individuals. On the other hand, the drug therapies segment helps in managing comorbid conditions like anxiety, depression, and ADHD.
Autism Spectrum Disorders Market Analysis by Region
The United States is expected to lead the market share, owing to the high prevalence of the disease in the region. The market is further driven by the application of novel technologies to cater to the unmet needs of patients. The regional market is also characterized by significant investment in R&D to advance research and develop innovative diagnostic tools. For instance, in December 2023, United States-based NeuroQure, an aspiring biotech startup focusing on gene therapy for neurocognitive disorders acquired exclusive rights to license a patent portfolio from CART (UC Irvine Center for Autism Research and Translation) with an investment of USD 14 million. The acquisition aims to deliver functional biomarkers to facilitate early diagnosis of the condition in newborns to enable early intervention.
The autism spectrum disorders market size is also influenced by the rising strategic partnerships among the key market players in the region. For example, in December 2023, Harmony Biosciences Holdings, Inc. acquired Zynerba Pharmaceuticals, Inc. in a deal worth USD 60 million. Harmony, headquartered in the United States, is a pioneering pharmaceutical company aiming to commercialize and develop innovative therapies for rare neurological diseases. It envisions expanding its product portfolio with multiple assets that address the unmet needs of autistic patients. This acquisition is expected to treat the symptoms of Fragile X syndrome as well. The increasing merger and acquisition activities are one of the prominent trends in the United States market which is projected to boost the market value in the forecast period.
Leading Players in the Autism Spectrum Disorders Market
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Abbvie Inc.
American pharmaceutical company Abbvie Inc. is known to invest in R&D activities to discover new treatments for neurological and psychiatric disorders, including autistic spectrum disorders. It is involved in the clinical development of drugs that address some of the comorbid conditions associated with ASD.
Jazz Pharmaceuticals
Jazz Pharmaceuticals, a United States-based global biopharmaceutical company, has a prominent presence in the market. The company is involved in developing therapeutics that have potential applications in addressing certain symptoms of ASD such as sleep and anxiety issues.
dfusion Inc.
This California-based company is known for its digital health innovations to address social and behavioral challenges and has significantly contributed to the autism spectrum disorders market growth. dfusion Inc. technology-based solutions such as digital therapeutic platforms and applications are aimed at improving the social skills and communication of ASD patients.
Novartis AG
Novartis AG, a global healthcare company based in Switzerland, focuses on developing innovative pharmaceuticals and is one of the leading players of the market. It is involved in the development of medications that target neurological and psychiatric conditions, some of which are used to manage ASD symptoms and comorbidities.
Other key players in the market include Johnson & Johnson Services, Inc., Curemark LLC, Bristol Myers Squibb Co., Axial Therapeutics, Q BioMed Inc., PaxMedica, Otsuka Pharmaceutical, Stalicla SA, and Zynerba Pharmaceuticals, Inc.
Key Questions Answered in the Autism Spectrum Disorders Market Report
Autism Spectrum Disorders Market Overview
Autism spectrum disorder (ASD) is a neurological disorder affecting a person's ability to interact, communicate, behave, and learn. It is termed as a ‘developmental disorder’ as the symptoms appear within the first two years of life. Diagnosis is generally based on a child’s behavior. Most children are diagnosed at the age of 4. Approximately 1 in 36 (around 2.8%) children have been identified with the condition, with boys being more susceptible to developing the disease than girls. The male-to-female disease prevalence is 4:1. Around 40% of the children diagnosed with autism are nonverbal, while 44% of them have the average or above-average intellectual ability and 31% may have an intellectual disability. It may also affect a child’s ability to move and pay attention.
The autism spectrum market demand is driven by the growing number of ASD cases which augments the need for effective therapies, diagnostic tools, and support services. ASD research and treatment programs are increasingly receiving financial backing from the government, which also affects market dynamics. The growth of digital therapeutics and apps further boosts the market share by providing interactive and personalized therapy options. Moreover, the rising development of new therapies to manage symptoms and comorbid conditions associated with ASD is likely to support market expansion.
Autism Spectrum Disorders Market Growth Drivers
Increasing Prevalence of Autism Spectrum Disorder Set to Fuel Market Growth
The prevalence rates vary across different regions, with some areas having higher prevalence rates. For instance, California has an incidence of 1 in 26 patients, while South Korea has 1 in 38 patients affected by autism. The market is driven by the increasing prevalence of the disease, as the cases reported in 2023 saw a surge of 317% compared to 2000. The prevalence rates in adults are comparatively lower than children. In the United States, approximately 2.2% of the adults are autistic. The increased focus on programs and services aimed at helping individuals with ASD transition to adulthood is anticipated to shape the market dynamics.
Emphasis on Treating Autism Associated Comorbidities to Affect the Autism Spectrum Disorders Market Value Significantly
Recent data reveals that 38% of the patients with ASD experience seizures while 40% suffer from anxiety. Sleep issues affect 53% of the people. The market value of autism spectrum disorders is boosted by the application of new technologies to address rare comorbidities associated with the disease. In February 2023, a group of Northwestern researchers devised a new therapy to treat Phelan-McDermid syndrome, which is a rare subtype of ASD. The new drug is designed to address cognitive function, and motor behavior deficiencies among others. Moreover, there is a key focus on expanding the existing treatment options for adults as well, which is poised to boost market size.
Autism Spectrum Disorders Market Trends
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
Rising Utilization of Mobile Applications to Manage Autism
One of the major market trends is the growing utilization of digital health solutions such as mobile apps for ASD management. For example, in May 2023, BlueSprig Pediatrics, a United States-based prominent autism therapy provider launched the Attend Behavior App to provide individualized and effective behavioral strategies for children suffering from autism, ADHD, and other behavioral conditions. With the app, parents can receive real-time support and guidance to help their children. The rising integration and utilization of mobile apps are expected to benefit the market growth in the forecast period.
Increased Collaborations to Develop Efficient Treatment
The autism spectrum disorders market share is influenced by the increased collaborations among the key market players. For instance, in June 2023, PaxMedica, Inc. entered a strategic partnership with PoloMar Health to investigate the use of emodin as a potential treatment for treating autism spectrum disorder. PoloMar Health is also working with the BRAIN Foundation as a part of this initiative. The rising collaborations amongst companies to deliver effective and efficient solutions are anticipated to bolster the market share.
Growing Focus on Alternative Therapies
One treatment cannot help all the patients, therefore, there has been increasing importance on developing new therapeutics that address a wider spectrum of symptoms in the autism spectrum disorders market. Behavior therapy, speech-language therapy, physical therapy, and occupational therapy are common treatment methods in the market. Applied behavior analysis is a prominent behavioral treatment with two discrete trial training and pivotal response training as major categories. In addition, the researchers are continuously working to identify new potential treatments.
Advancements in Diagnosis and Treatment
The market is witnessing increased use of artificial intelligence (AI) and machine learning (ML) to facilitate early diagnosis and personalized treatment plans, with AI-driven tools showing the potential to improve the accuracy of autism spectrum disorder diagnosis. Moreover, advancements in wearable technology, such as smartwatches and biosensors, to monitor behavioral and physiological indicators in real time are expected to support the market expansion.
Autism Spectrum Disorders Market Segmentation
Autism Spectrum Disorders Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- Autistic Disorder
- Asperger’s Syndrome
- Pervasive Development Disorder (PDD)
- Others
- Communication and Behavioral Therapies
- Drug Therapies
Market Breakup by Age Group
- Child
- Adult
- Oral
- Parenteral
- United States
- EU-4 and the United Kingdom
- Japan
- India
Market Segmentation Based on Application Areas is Anticipated to Witness Substantial Growth
Based on the treatment type, the market is segmented into communication and behavioral therapies and drug therapies. Communication and behavioral therapies include applied behavior analysis (ABA), speech and language therapy, and occupational therapy, among others, whereas drug therapies are further segmented into antipsychotic drugs, selective serotonin reuptake inhibitors (SSRIs), stimulants, and sleep medications, among others.
The communication and behavioral therapies segment holds a significant share of the autism spectrum disorders market. This can be attributed to the established effectiveness of behavioral therapies in improving the quality of life for people living with autism spectrum disorder. Behavioral therapies, such as applied behavior analysis (ABA), are widely used to improve social skills, communication, and adaptive behaviors in ASD individuals. On the other hand, the drug therapies segment helps in managing comorbid conditions like anxiety, depression, and ADHD.
Autism Spectrum Disorders Market Analysis by Region
The United States is expected to lead the market share, owing to the high prevalence of the disease in the region. The market is further driven by the application of novel technologies to cater to the unmet needs of patients. The regional market is also characterized by significant investment in R&D to advance research and develop innovative diagnostic tools. For instance, in December 2023, United States-based NeuroQure, an aspiring biotech startup focusing on gene therapy for neurocognitive disorders acquired exclusive rights to license a patent portfolio from CART (UC Irvine Center for Autism Research and Translation) with an investment of USD 14 million. The acquisition aims to deliver functional biomarkers to facilitate early diagnosis of the condition in newborns to enable early intervention.
The autism spectrum disorders market size is also influenced by the rising strategic partnerships among the key market players in the region. For example, in December 2023, Harmony Biosciences Holdings, Inc. acquired Zynerba Pharmaceuticals, Inc. in a deal worth USD 60 million. Harmony, headquartered in the United States, is a pioneering pharmaceutical company aiming to commercialize and develop innovative therapies for rare neurological diseases. It envisions expanding its product portfolio with multiple assets that address the unmet needs of autistic patients. This acquisition is expected to treat the symptoms of Fragile X syndrome as well. The increasing merger and acquisition activities are one of the prominent trends in the United States market which is projected to boost the market value in the forecast period.
Leading Players in the Autism Spectrum Disorders Market
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Abbvie Inc.
American pharmaceutical company Abbvie Inc. is known to invest in R&D activities to discover new treatments for neurological and psychiatric disorders, including autistic spectrum disorders. It is involved in the clinical development of drugs that address some of the comorbid conditions associated with ASD.
Jazz Pharmaceuticals
Jazz Pharmaceuticals, a United States-based global biopharmaceutical company, has a prominent presence in the market. The company is involved in developing therapeutics that have potential applications in addressing certain symptoms of ASD such as sleep and anxiety issues.
dfusion Inc.
This California-based company is known for its digital health innovations to address social and behavioral challenges and has significantly contributed to the autism spectrum disorders market growth. dfusion Inc. technology-based solutions such as digital therapeutic platforms and applications are aimed at improving the social skills and communication of ASD patients.
Novartis AG
Novartis AG, a global healthcare company based in Switzerland, focuses on developing innovative pharmaceuticals and is one of the leading players of the market. It is involved in the development of medications that target neurological and psychiatric conditions, some of which are used to manage ASD symptoms and comorbidities.
Other key players in the market include Johnson & Johnson Services, Inc., Curemark LLC, Bristol Myers Squibb Co., Axial Therapeutics, Q BioMed Inc., PaxMedica, Otsuka Pharmaceutical, Stalicla SA, and Zynerba Pharmaceuticals, Inc.
Key Questions Answered in the Autism Spectrum Disorders Market Report
- What was the autism spectrum disorders market value in 2023?
- What is the autism spectrum disorders market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on disease type?
- What is the marketn based on the route of administration?
- What are the major factors aiding the breakup based on treatment type?
- What is the market breakup by age group?
- What is market segmentatioautism spectrum disorders market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of autism spectrum disorder affect the market landscape?
- What are the major autism spectrum disorders market trends?
- Which disease type will dominate the market share?
- Which treatment type is expected to have a high market value in the coming years?
- Which age group is projected to elevate market growth in the forecast period?
- Which route of administration will experience the highest demand in the market segment?
- Who are the key players involved in the autism spectrum disorders market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Autism Spectrum Disorders Market Overview: 8 Major Market
- 3.1 Autism Spectrum Disorders Market Historical Value (2018-2024)
- 3.2 Autism Spectrum Disorders Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Autism: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Autism Spectrum Disorders Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Autism Spectrum Disorders Market Landscape: 8 Major Market*
- 8.1 Autism Spectrum Disorders Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Autism Spectrum Disorders Market: Product Landscape
- 8.2.1 Analysis by Disease Type
- 8.2.2 Analysis by Treatment Type
- 8.2.3 Analysis by Age Group
- 8.2.4 Analysis by Route of Administration
- 9 Autism Spectrum Disorders Market Therapy Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Autism Spectrum Disorders: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Autism Spectrum Disorders Market Segmentation: 8 Major Market
- 12.1 Autism Spectrum Disorders Market by Disease Type
- 12.1.1 Market Overview
- 12.1.2 Autistic Disorder
- 12.1.3 Asperger’s Syndrome
- 12.1.4 Pervasive Development Disorder (PDD)
- 12.1.5 Others
- 12.2 Autism Spectrum Disorders Market by Treatment Type
- 12.2.1 Market Overview
- 12.2.2 Communication and Behavioral Therapies
- 12.2.2.1 Applied Behavior Analysis (ABA)
- 12.2.2.2 Speech and Language Therapy
- 12.2.2.3 Occupational Therapy
- 12.2.2.4 Others
- 12.2.3 Drug Therapies
- 12.2.3.1 Antipsychotic Drugs
- 12.2.3.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 12.2.3.3 Stimulants
- 12.2.3.4 Sleep Medications
- 12.2.3.5 Others
- 12.3 Autism Spectrum Disorders Market by Age Group
- 12.3.1 Market Overview
- 12.3.2 Child
- 12.3.3 Adult
- 12.4 Autism Spectrum Disorders Market by Route of Administration
- 12.4.1 Market Overview
- 12.4.2 Oral
- 12.4.3 Parenteral
- 12.5 Autism Spectrum Disorders Market by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Autism Spectrum Disorders Market (218-2034)
- 13.1 United States Autism Spectrum Disorders Market Historical Value (2018-2024)
- 13.2 United States Autism Spectrum Disorders Market Forecast Value (2025-2034)
- 13.3 United States Autism Spectrum Disorders Market by Disease Type
- 13.3.1 Market Overview
- 13.3.2 Autistic Disorder
- 13.3.3 Asperger’s Syndrome
- 13.3.4 Pervasive Development Disorder (PDD)
- 13.3.5 Others
- 13.4 United States Autism Spectrum Disorders Market by Treatment Type
- 13.4.1 Market Overview
- 13.4.2 Communication and Behavioral Therapies
- 13.4.2.1 Applied Behavior Analysis (ABA)
- 13.4.2.2 Speech and Language Therapy
- 13.4.2.3 Occupational Therapy
- 13.4.2.4 Others
- 13.4.3 Drug Therapies
- 13.4.3.1 Antipsychotic Drugs
- 13.4.3.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 13.4.3.3 Stimulants
- 13.4.3.4 Sleep Medications
- 13.4.3.5 Others
- 13.5 United States Autism Spectrum Disorders Market by Age Group
- 13.5.1 Market Overview
- 13.5.2 Child
- 13.5.3 Adult
- 13.6 United States Autism Spectrum Disorders Market by Route of Administration
- 13.6.1 Market Overview
- 13.6.2 Oral
- 13.6.3 Parenteral
- 14 EU-4 and United Kingdom Autism Spectrum Disorders Market (218-2034)
- 14.1 EU-4 and United Kingdom Autism Spectrum Disorders Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Autism Spectrum Disorders Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Autism Spectrum Disorders Market by Disease Type
- 14.3.1 Market Overview
- 14.3.2 Autistic Disorder
- 14.3.3 Asperger’s Syndrome
- 14.3.4 Pervasive Development Disorder (PDD)
- 14.3.5 Others
- 14.4 EU-4 and United Kingdom Autism Spectrum Disorders Market by Treatment Type
- 14.4.1 Market Overview
- 14.4.2 Communication and Behavioral Therapies
- 14.4.2.1 Applied Behavior Analysis (ABA)
- 14.4.2.2 Speech and Language Therapy
- 14.4.2.3 Occupational Therapy
- 14.4.2.4 Others
- 14.4.3 Drug Therapies
- 14.4.3.1 Antipsychotic Drugs
- 14.4.3.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 14.4.3.3 Stimulants
- 14.4.3.4 Sleep Medications
- 14.4.3.5 Others
- 14.5 EU-4 and United Kingdom Autism Spectrum Disorders Market by Age Group
- 14.5.1 Market Overview
- 14.5.2 Child
- 14.5.3 Adult
- 14.6 EU-4 and United Kingdom Autism Spectrum Disorders Market by Route of Administration
- 14.6.1 Market Overview
- 14.6.2 Oral
- 14.6.3 Parenteral
- 15 Japan Autism Spectrum Disorders Market
- 15.1 Japan Autism Spectrum Disorders Market Historical Value (2018-2024)
- 15.2 Japan Autism Spectrum Disorders Market Forecast Value (2025-2034)
- 15.3 Japan Autism Spectrum Disorders Market by Disease Type
- 15.3.1 Market Overview
- 15.3.2 Autistic Disorder
- 15.3.3 Asperger’s Syndrome
- 15.3.4 Pervasive Development Disorder (PDD)
- 15.3.5 Others
- 15.4 Japan Autism Spectrum Disorders Market by Treatment Type
- 15.4.1 Market Overview
- 15.4.2 Communication and Behavioral Therapies
- 15.4.2.1 Applied Behavior Analysis (ABA)
- 15.4.2.2 Speech and Language Therapy
- 15.4.2.3 Occupational Therapy
- 15.4.2.4 Others
- 15.4.3 Drug Therapies
- 15.4.3.1 Antipsychotic Drugs
- 15.4.3.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 15.4.3.3 Stimulants
- 15.4.3.4 Sleep Medications
- 15.4.3.5 Others
- 15.5 Japan Autism Spectrum Disorders Market by Age Group
- 15.5.1 Market Overview
- 15.5.2 Child
- 15.5.3 Adult
- 15.6 Japan Autism Spectrum Disorders Market by Route of Administration
- 15.6.1 Market Overview
- 15.6.2 Oral
- 15.6.3 Parenteral
- 16 India Autism Spectrum Disorders Market
- 16.1 India Autism Spectrum Disorders Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Autism Spectrum Disorders Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Autism Spectrum Disorders Market by Disease Type
- 16.3.1 Market Overview
- 16.3.2 Autistic Disorder
- 16.3.3 Asperger’s Syndrome
- 16.3.4 Pervasive Development Disorder (PDD)
- 16.3.5 Others
- 16.4 India Autism Spectrum Disorders Market by Treatment Type
- 16.4.1 Market Overview
- 16.4.2 Communication and Behavioral Therapies
- 16.4.2.1 Applied Behavior Analysis (ABA)
- 16.4.2.2 Speech and Language Therapy
- 16.4.2.3 Occupational Therapy
- 16.4.2.4 Others
- 16.4.3 Drug Therapies
- 16.4.3.1 Antipsychotic Drugs
- 16.4.3.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 16.4.3.3 Stimulants
- 16.4.3.4 Sleep Medications
- 16.4.3.5 Others
- 16.5 India Autism Spectrum Disorders Market by Age Group
- 16.5.1 Market Overview
- 16.5.2 Child
- 16.5.3 Adult
- 16.6 India Autism Spectrum Disorders Market by Route of Administration
- 16.6.1 Market Overview
- 16.6.2 Oral
- 16.6.3 Parenteral
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Abbvie Inc .
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Mergers and Acquisitions
- 23.2.5 Certifications
- 23.3 Jazz Pharmaceuticals
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Mergers and Acquisitions
- 23.3.5 Certifications
- 23.4 dfusion Inc.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Mergers and Acquisitions
- 23.4.5 Certifications
- 23.5 Novartis AG
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Mergers and Acquisitions
- 23.5.5 Certifications
- 23.6 Johnson & Johnson Services, Inc.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Mergers and Acquisitions
- 23.6.5 Certifications
- 23.7 Curemark LLC
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 23.8 Bristol Myers Squibb Co .
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Mergers and Acquisitions
- 23.8.5 Certifications
- 23.9 Axial therapeutics
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Mergers and Acquisitions
- 23.9.5 Certifications
- 23.10 Q BioMed Inc .
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Mergers and Acquisitions
- 23.10.5 Certifications
- 23.11 PaxMedica
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Mergers and Acquisitions
- 23.11.5 Certifications
- 23.12 Otsuka Pharmaceutica
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Mergers and Acquisitions
- 23.12.5 Certifications
- 23.13 Stalicla SA
- 23.13.1 Financial Analysis
- 23.13.2 Product Portfolio
- 23.13.3 Demographic Reach and Achievements
- 23.13.4 Mergers and Acquisitions
- 23.13.5 Certifications
- 23.14 Zynerba Pharmaceuticals, Inc .
- 23.14.1 Financial Analysis
- 23.14.2 Product Portfolio
- 23.14.3 Demographic Reach and Achievements
- 23.14.4 Mergers and Acquisitions
- 23.14.5 Certifications
- 24 Autism Spectrum Disorders Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
